Britannia Pharmaceuticals
Generated by Meeveem AI
"Develops specialty pharmaceutical treatments for Parkinson's Disease and Schizophrenia."
Reading
•51 - 250 Employees
•Pharmaceuticals
About Britannia Pharmaceuticals
Britannia Pharmaceuticals is a specialty pharmaceutical company developing and marketing treatments for Parkinson's Disease and Schizophrenia. Operating as the Global Specialty Centre for Parkinson's Disease within the STADA Network, the company has pioneered innovative therapies since 1982, providing a comprehensive Package of Care that includes education and support for healthcare professionals and patients. The company serves patients across 30 countries, combining decades of neurology expertise with high quality, ethical treatment development. Britannia addresses the challenges of chronic neurological conditions, helping individuals maintain quality of life through specialty medicines designed for serious medical needs.
120
Team Members
1982
Founded
Pharmaceuticals
Sector
Hybrid
Work Environment
Our Vision
A world where individuals with chronic neurological conditions can maintain quality of life through accessible, innovative specialty treatments that deliver meaningful outcomes.
Our Mission
At Britannia Pharmaceuticals, our mission is to care for people's health as a trusted partner by developing innovative specialty pharmaceutical solutions that enhance quality of life for individuals with Parkinson's Disease and Schizophrenia.